Systemic bioimpedance analysis in patients with implanted cardiac stimulation devices  by Fabregat-Andrés, Óscar et al.
15;35(3):340–346 345
S sis in patients with implanted
c
A ca en pacientes portadores
d rdiaca
D
T
w
u
r
B
c
t
q
h
e
a
d
i
t
t
3
f
a
t
t
i
l
w
d
t
w
t
b
T
d
a
o
(
m
h
e
Table 1 – Characteristics of the study population.
Variable (n=21) Value
Age (years) 73±8.2
Male (n, %) 12 (57)
Time since ﬁrst implant 9 (3–12)
LV ejection fraction (%) 35.5±7.4
Type of device (n, %)
Pacemaker 13
CRT-D 8
Implant diagnosis (n, %)
Sick sinus syndrome 6 (28)
Atrio-ventricular block 5 (24)
Sudden death primary prevention 6 (28)
Sudden death secondary prevention 2 (9)
Others 2 (9)
Device brand (n, %)
Medtonic 7 (33)
Biotronik 6 (28)
St. Jude Medical 3 (14)
Boston Scientiﬁc 2 (9)
Vitatron Medical 2 (9)
Sorin Group 1 (5)
Cardiac rhythm during the analysis (n, %)
Sinus 11 (52)
Atrial ﬁbrillation 4 (19)
Bicameral stimulation 3 (14)
Ventricular stimulation 3 (14)
Bioimpedance value
BIVA (%) 75.7±4.9
Results expressed as median± standard deviation (quantitative
variables), or in numbers and percentages (qualitative variables).
CRT-D: cardiac resynchronization therapy with deﬁbrillator; LV: left
ventricle; BIVA: systemic bioimpedance vector analysis.nefrolog ia. 20
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nálisis de bioimpedancia sistémi
e dispositivos de estimulación ca
ear Editor,
he systemic bioimpedance vector analysis (BIVA) is amethod
idely utilized to assess body composition and systemic vol-
me overload in both patientswith heart failure and advanced
enal failure. Recent studies have shown the superiority of
IVA in the estimation of ﬂuid overload over strict clinical
riteria during haemodialysis sessions.1 The use of BIVA in
his context helps to improve ﬂuid control, blood pressure,
uality life scores, and also predicts clinical outcome such as
ospitalizations due to cardiovascular causes.2
The population with cardiac stimulation devices increases
very year, particularly within our patient population. The
nnual consumption of conventional generators and car-
iac resynchronization devices with or without deﬁbrillator
s estimated to be 745.8 and 53.1 units per million inhabi-
ants respectively. This is the most recent data obtained by
he Spanish Society of Cardiology, considering that there are
5,000 implants per year in Spain.3
Although it is not well known whether BIVA can affect the
unction of cardiac stimulation devices, most manufacturers
nd even clinical practice guidelines4 advice against its use in
his group of patients, due to the risk of electrical interference
hat may result in signal oversensing, stimulation inhibition,
nappropriate deﬁbrillator shocks or other functional anoma-
ies. These restrictions limit the use of BIVA in many patients
ith a history of cardiopathy, particularly for those with car-
iac failure.
As a consequence,we decided to assess if BIVA caused elec-
romagnetic interference or generator malfunction in patients
ith cardiac stimulation devices. To do this, all admissions
o our centre due to acute decompensation of cardiac failure
etween January and June 2014 were prospectively studied.
he analysis was performed prior to discharge, using a Car-
ioEFGTM model at a frequency of 50kHz. The study was
uthorized by the Clinical Trials and Research Committee of
ur centre. Out of 77 patients studied, 21 had cardiac device
Table 1). Prior to BIVA, all generators and wires showed nor-
al function. During BIVA, it was not detected any effects on
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intracavitary electrocardiograms, we did not observe any
inappropriate sensing in channels. No telemetric interfer-
ences were observed between the cardiac device and the
programming device either. Upon repetition of the interro-
gation after BIVA, no changes in the wire parameters nor
alterations in the functioning of the generator device were
detected in any of the patients.
Literature on the safety of bioimpedance analysis of the
body in patients with cardiac stimulation devices is scarce,
although due to widespread use evidence of safety is needed.
Recently, Buch et al.5 found no alterations in the generators
during the use of BIVA, in a cohort of 20 outpatients with
chronic cardiac failure. In this study, as in ours, there is a lim-
ited number of patients and the use of a single system of anal-
ysis. Nevertheless both studies suggest that the use of BIVA in
patients with cardiac devices is safe within this context.
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